Analysis for ZBH

📈 Growth & Financial Trajectory

Over 8 quarters, Revenue rose from about 1.824B in 2024 Q3 to 2.177B in 2026 Q2, a gain near 19%. Net income fluctuated, starting at 249.3M and ending at 199.6M, with troughs in mid-2025 before rebounding in early 2026. The trend shows robust top-line growth with dispersion in profitability.

💰 Margins & Cash Flow

Gross margin stays high around ~70%, with Gross Profit ~1.28-1.54B on ~2.0-2.2B in revenues across the period. Operating margin has run mid-teens to upper teens (approx 15-18%), reflecting steady operating leverage. Cash flow from operating activities was consistently positive (e.g., ~506-517M in 2024-25 periods, ~359-447M in 2026), while investing activities consumed cash and financing activities varied, resulting in a small negative net cash flow in most latest quarters.

🛡️ Balance Sheet & Liquidity

Total Assets ~$21.8-22.8B, Equity ~$12.3-12.7B, Liabilities ~$9.8-10.8B, with a solid current ratio around 1.7x. Balance sheet shows healthy liquidity and moderate leverage (Liabilities/Equity around 0.8x). Intangible assets are sizeable but managed within equity base.

⚠️ Key Drivers & Risks

• Drivers: Aging population and strong demand for orthopedic implants; increasing adoption of MIS devices and reconstructive procedures.
• Risks: Cyclicality of surgical volumes, competitive pricing pressure, potential regulatory or reimbursement shifts.